• Теги
    • избранные теги
    • Компании2711
      • Показать ещё
      Разное619
      • Показать ещё
      Страны / Регионы479
      • Показать ещё
      Международные организации64
      • Показать ещё
      Люди67
      • Показать ещё
      Формат15
      Показатели33
      • Показать ещё
      Издания23
      • Показать ещё
      Сферы3
17 сентября, 05:30

Healthcare innovation — a vital social function

FORTY years ago no one could have foreseen the staggering development Shanghai was about to witness when it started to reform its economy and open up to international trade. In record time, the city

15 сентября, 17:55

Oncology Space in Focus this Week on ESMO Presentations

There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

15 сентября, 00:39

4 Biotech Stocks That Show Promise on Sustainable Growth

Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

15 сентября, 00:01

Biosimilar 2017 Progress Report: Stocks in Focus

The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.

14 сентября, 18:00

Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

14 сентября, 01:08

Roche (RHHBY) Announces Data on Respiratory Drug Esbriet

Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.

13 сентября, 17:47

Array's NDAs for Melanoma Combo Accepted for Review by FDA

Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

Выбор редакции
12 сентября, 18:27

Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA

Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.

Выбор редакции
12 сентября, 01:56

5 Ways To Play The Biotech Bull Market

This is a bull market, and some biotech stocks are the real raging bulls—especially when massive drug pipelines are at stake, and landmark FDA approvals shake things up with massive share price momentum. The FDA’s approval just over a week ago of giant Novartis’ new class of cancer drug is a case in point. This was a landmark ruling, and Novartis now holds the status as the first company to win approval for a new class of cancer drug, its CAR-T Kymriah. Nothing shakes up the biotech world like an FDA approval, or even hints that…

11 сентября, 16:42

Roche's Ophthalmology Drug Fails to Meet Primary Endpoint

Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.

11 сентября, 16:33

5 Top-Ranked Biotech Stocks to Buy Right Now

If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

11 сентября, 16:22

Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis

North Korea-related tensions weighed on stocks across the world last week.

Выбор редакции
31 августа, 02:31

US approves first cancer drug to use patient's own cells – with $475,000 price tag

Novartis medication marketed as Kymriah treats most common type of childhood cancer, but some fear it could spur wave of highly expensive drugsUS regulators approved the first cancer drug that uses a patient’s own cells to fight cancer. But the drug is priced at $475,000. Oncologists described the drug, made by Novartis and marketed as Kymriah, as revolutionary, but critics worried the first-of-its-kind cancer treatment could usher in a new class of ultra-expensive medications. Continue reading...

30 июня, 19:04

Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA

Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).

30 июня, 15:15

Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

29 июня, 22:53

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

29 июня, 16:54

Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

29 июня, 16:30

Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

Выбор редакции
29 июня, 07:00

4 европейские компании, чьи акции нужно купить сейчас

  • 0

Почему стоит обратить внимание на огромные европейские корпорации, такие как Novartis, HSBC, Volkswagen и Unilever.